RECRUITING Phase 2 ClinicalTrials.gov

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Sponsor: National Cancer Institute (NCI) • ClinicalTrials.gov ID: NCT07504588

Registry updated: 2026-10-20

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial response to platinum therapy (platinum-sensitive), that has progressed after poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor maintenance therapy (recurrent), and that has a mutation in the BRCA1 or BRCA2 genes or is homologous recombination deficient. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Giving sacituzumab govitecan and bevacizumab may kill more tumor cells than standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with recurrent platinum-sensitive ovarian cancers that have BRCA1/2 mutations or homologous recombination deficiency.

Interventions

Anti-VEGF Monoclonal Antibody (Biological)
Given IV
Bevacizumab (Biological)
Given IV
Biospecimen Collection (Procedure)
Undergo collection of blood samples
Carboplatin (Drug)
Given IV
Computed Tomography (Procedure)
Undergo CT
Echocardiography Test (Procedure)
Undergo ECHO
Gemcitabine (Drug)
Given IV
Magnetic Resonance Imaging (Procedure)
Undergo MRI
Multigated Acquisition Scan (Procedure)
Undergo MUGA
Pegylated Liposomal Doxorubicin Hydrochloride (Drug)
Given IV
Sacituzumab Govitecan (Biological)
Given IV

Eligibility criteria

Inclusion Criteria: * Patients must have histologic diagnosis of high grade serous or endometrioid epithelial ovarian cancer * Ovarian cancer = fallopian tube, ovarian, and primary peritoneal cancer * Disease must be platinum sensitive, as defined by progression documented ≥ 6 months (182 days) from the last receipt of platinum * Disease must have progressed during first line maintenance PARP inhibitor (PARPi) for advanced ovarian cancer. NO intervening therapies between progression on PARPi and study registration are permitted * Disease must be germline or somatic BRCA1 or BRCA2 mutated or homologous recombination deficiency test positive * Disease must be measurable or non-measurable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v.) 1.1 * Secondary or cytoreductive surgery, after start of treatment on this trial, and prior to documentation of disease progression, is NOT permitted * No previous receipt of any topoisomerase-I inhibiting agents * No investigational agents within 4 weeks of study registration * No current treatment with any other (non-study) cytotoxic chemotherapy, targeted therapy, biologic therapy, immunotherapy or endocrine therapy for the treatment of the disease under the current study * Last dose of PARP inhibitor treatment must be ≥ 3 weeks before study registration * Patients with treated brain metastases are eligible if follow-up brain imaging 4 weeks after CNS-directed therapy shows no evidence of disease progression. Patients with brain metastases must have follow up imaging demonstrating no evidence of disease progression and that the disease is stable off of steroids * Age ≥ 18 * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 * Not pregnant and not nursing * Absolute neutrophil count (ANC) ≥ 1,500 cells/mm\^3 * Platelets ≥ 100,000 cells/mm\^3 * Hemoglobin ≥ 9 g/dl (Note: The use of transfusion or other intervention to achieve hemoglobin \[Hgb\] ≥ 9 g/dl is acceptable) * Creatinine clearance (CrCL) of ≥ 30 mL/min by the Cockcroft-Gault formula * Urinalysis with ≤ 1+ protein and/or urine protein \< 1.0 g/24 hours (hrs) * Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional ULN * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification. To be eligible for this trial, patients should be class 2B or better * No active infection requiring parenteral antibiotics * No non-healing wound, ulcer, or bone fracture * No current evidence of intra-abdominal abscess, abdominal/pelvic fistula (not diverted), gastrointestinal perforation, gastrointestinal (GI) obstruction, and/or need for drainage nasogastric or gastrostomy tube * No clinically significant bleeding within 28 days prior to registration * No uncontrolled hypertension, defined as systolic ≥ 160 mm Hg or diastolic ≥ 100 mm Hg * Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) with the following exceptions: * Patients with grade 2 or lower neuropathy, any grade alopecia, well controlled hypertension, thyroid disease controlled with therapy, and history of thromboembolic disease on anticoagulation are eligible * Patients with laboratory-based grade 2 or higher adverse events (AEs) that meet the criteria outlined above are eligible * No major surgery within 3 weeks prior to study registration * Patients who underwent major surgery must have recovered adequately from any toxicity and/or complications from surgery prior to study registration * No strong inhibitors or inducers of UGT1A1 * No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent(s) (or any of its excipients)

Conditions

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma Recurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma Recurrent Platinum-Sensitive Ovarian High Grade Serous Adenocarcinoma Recurrent Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma Recurrent Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma

Locations

Highlands Oncology Group - Fayetteville — Fayetteville, Arkansas, United States
Highlands Oncology Group - Rogers — Rogers, Arkansas, United States
Highlands Oncology Group — Springdale, Arkansas, United States
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho, United States
Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho, United States
Kootenai Clinic Cancer Services - Sandpoint — Sandpoint, Idaho, United States
Mercy Hospital — Cedar Rapids, Iowa, United States
Oncology Associates at Mercy Medical Center — Cedar Rapids, Iowa, United States
Mercy Hospital Springfield — Springfield, Missouri, United States
Billings Clinic Cancer Center — Billings, Montana, United States
Benefis Sletten Cancer Institute — Great Falls, Montana, United States
Logan Health Medical Center — Kalispell, Montana, United States
Community Medical Center — Missoula, Montana, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment